NCT07743580 — SARS-CoV-2 trial site landscape

Public-registry site landscape for NCT07743580, “A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease”, a SARS-CoV-2 study sponsored by Shionogi. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07743580 (registry record)
Study title	A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
Official title	A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease
Sponsor	Shionogi
Condition(s)	SARS-CoV-2
Phase	PHASE3
Listed sites	27
Site countries	United States, Bulgaria, Japan

Patient-friendly overview of this study: eichor.com/study/NCT07743580.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07743580 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →